Kevin T. Conroy, CEO of Madison’s Exact Sciences Corp., recently sat down with The Wall Street Journal to discuss the background and future of the molecular-diagnostics company. Exact Sciences is committed to playing a role in the eradication of colorectal cancer, and its Cologuard product is the first noninvasive screening test for colorectal cancer that analyzes both stool DNA and blood biomarkers. In August 2014, Cologuard gained approval from the Food and Drug Administration.

Read the Wall Street Journal interview with Conroy here, and for more information about Exact Sciences, please visit: